Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Feb '26 Feb 28, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	2020 - 2016
Revenue	0.03	0.01	-	-	-	-	Upgrade
Cost of Revenue	0.03	0.01	-	-	-	-	Upgrade
Selling, General & Admin	2.35	2.08	1.1	0.99	1.45	1.23	Upgrade
Operating Expenses	2.81	2.89	1.51	1.22	1.61	1.97	Upgrade
Operating Income	-2.81	-2.89	-1.51	-1.22	-1.61	-1.97	Upgrade
Other Non Operating Income (Expenses)	-0.53	-0.64	-0.18	-0.12	-0.15	-0.08	Upgrade
EBT Excluding Unusual Items	-3.34	-3.53	-1.7	-1.35	-1.75	-2.05	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-	-0.01	-	Upgrade
Asset Writedown	-	-	-0.01	-0.05	-	-	Upgrade
Other Unusual Items	-	-	-	-0	0	-	Upgrade
Pretax Income	-3.34	-3.53	-1.71	-1.4	-1.75	-2.05	Upgrade
Net Income	-3.34	-3.53	-1.71	-1.4	-1.75	-2.05	Upgrade
Net Income to Common	-3.34	-3.53	-1.71	-1.4	-1.75	-2.05	Upgrade
Shares Outstanding (Basic)	171	166	138	131	108	95	Upgrade
Shares Outstanding (Diluted)	171	166	138	131	108	95	Upgrade
Shares Change (YoY)	19.61%	20.37%	5.46%	21.03%	13.89%	34.24%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.01	-0.01	-0.02	-0.02	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.01	-0.01	-0.02	-0.02	Upgrade
Free Cash Flow	-2.28	-3.16	-0.47	-1.17	-2	-2.09	Upgrade
Free Cash Flow Per Share	-0.01	-0.02	-0.00	-0.01	-0.02	-0.02	Upgrade
Operating Margin	-9072.67%	-24758.85%	-	-	-	-	Upgrade
Profit Margin	-10796.28%	-30231.56%	-	-	-	-	Upgrade
Free Cash Flow Margin	-7373.87%	-27067.31%	-	-	-	-	Upgrade
EBITDA	-2.81	-2.89	-1.51	-1.22	-1.6	-1.97	Upgrade
D&A For EBITDA	0	0	0	0	0.01	0.01	Upgrade
EBIT	-2.81	-2.89	-1.51	-1.22	-1.61	-1.97	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.